摘要
目的探讨恩替卡韦对失代偿期乙型肝炎肝硬化患者肝功能的改善作用。方法选取2009年1月-2011年4月医院进行治疗的60例失代偿期乙型肝炎肝硬化患者为研究对象,将其随机分为对照组(常规治疗组)和观察组(加用恩替卡韦组)各30例,将两组患者治疗前及治疗后12、24周的血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红质(TB)水平及Child-Pugh评分进行比较。结果观察组治疗后12周血清ALT、AST、TB水平及Child-Pugh评分分别为(202.5±31.4)U/L、(198.4±32.5)U/L、(78.7±12.1)μmol/L、(7.2±1.2)分,治疗后24周血清ALT、AST、TB水平及Child-Pugh评分分别为(50.3±12.5)U/L、(52.3±11.9)U/L、(35.7±6.1)μmol/L、(6.1±1.1)分,均低于对照组,差异均有统计学意义(P<0.05)。结论恩替卡韦对失代偿期乙型肝炎肝硬化患者肝功能的改善作用显著,可用于此类患者的治疗。
OBJECTIVE To evaluate the effect of entecavir on the improvement of liver function of the patients with decompensated cirrhosis.METHODS A total of 60 patients with decompensated liver cirrhosis who enrolled in hospital from Jan 2009 to Apr 2011 were chosen as the research subjects and randomly divided into the control group（conventional treatment group） and the observation group（plus entecavir group） with 30 cases in each.The serum ALT,AST,and TB levels and Child-Pugh scores for the two groups of patients 12 and 24 weeks before and after the treatment were compared.RESULTS The serum ALT,AST,and TB levels and the Child-Pugh scores of the observation group 12 weeks after treatment were（202.5 ± 31.4） U/L,（198.4 ± 32.5） U/L,（78.7±12.1） μmol/L,and（7.2±1.2） points,respectively,while the serum ALT,AST,and TB levels and Child-Pugh scores 24 weeks after the treatment were respectively（50.3±12.5）U/L,（52.3±11.9）U/L,（35.7±6.1）μmol/L,and（6.1±1.1） points,which were lower than the control group,the differences were statistically significant（P〈0.05）.CONCLUSION Entecavir has significant effect on the improvement of the liver function of the patients with decompensated cirrhosis,which is suitable for the treatment of decompensated cirrhosis.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2012年第11期2404-2405,共2页
Chinese Journal of Nosocomiology
